Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Tarsons Products
TARSONS
Tarsons Products
Rising Global Healthcare Spending And Automation Will Expand Lab Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
30 Jul 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
₹760.00
50.8% undervalued
intrinsic discount
09 Aug
₹373.75
Loading
1Y
-24.0%
7D
-0.3%
Author's Valuation
₹760.0
50.8% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
₹760.0
50.8% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
6b
2019
2021
2023
2025
2027
2028
Revenue ₹6.3b
Earnings ₹1.2b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
13.39%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
13.77%
Calculation
₹1.19b
Earnings '28
x
48.73x
PE Ratio '28
=
₹58.20b
Market Cap '28
₹58.20b
Market Cap '28
/
51.94m
No. shares '28
=
₹1.12k
Share Price '28
₹1.12k
Share Price '28
Discounted to 2025 @ 13.77% p.a.
=
₹760.86
Fair Value '25